Blueprint Medicines (BPMC) to Release Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC) will be announcing its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.65) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The business had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. During the same quarter in the previous year, the company posted ($2.65) EPS. The company’s revenue was up 85.5% compared to the same quarter last year. On average, analysts expect Blueprint Medicines to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Blueprint Medicines Price Performance

NASDAQ:BPMC opened at $92.29 on Wednesday. The firm has a market capitalization of $5.65 billion, a price-to-earnings ratio of -11.04 and a beta of 0.63. The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66. The business has a 50 day simple moving average of $90.36 and a 200-day simple moving average of $78.32. Blueprint Medicines has a 1 year low of $43.89 and a 1 year high of $101.00.

Analyst Upgrades and Downgrades

Several brokerages have commented on BPMC. Citigroup raised their target price on shares of Blueprint Medicines from $54.00 to $65.00 and gave the stock a “sell” rating in a research report on Friday, February 16th. Stifel Nicolaus lifted their target price on Blueprint Medicines from $95.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th. Barclays upped their target price on Blueprint Medicines from $58.00 to $70.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 13th. Wedbush restated an “outperform” rating and set a $97.00 price target on shares of Blueprint Medicines in a research note on Monday, February 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a research note on Monday, February 26th. Four equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Blueprint Medicines presently has an average rating of “Hold” and a consensus target price of $85.43.

Insiders Place Their Bets

In other news, CFO Michael Landsittel sold 5,000 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $95.00, for a total value of $475,000.00. Following the completion of the transaction, the chief financial officer now directly owns 47,286 shares in the company, valued at $4,492,170. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO Michael Landsittel sold 5,000 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $95.00, for a total transaction of $475,000.00. Following the completion of the transaction, the chief financial officer now directly owns 47,286 shares in the company, valued at $4,492,170. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kate Haviland sold 12,464 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.69, for a total value of $1,130,360.16. Following the sale, the chief executive officer now directly owns 153,177 shares in the company, valued at $13,891,622.13. The disclosure for this sale can be found here. In the last quarter, insiders have sold 117,289 shares of company stock valued at $10,361,913. Insiders own 3.88% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.